ACADIA Pharmaceuticals Inc. (ACAD): Price and Financial Metrics

ACADIA Pharmaceuticals Inc. (ACAD)

Today's Latest Price: $46.45 USD

0.90 (-1.90%)

Updated Oct 30 4:00pm

Add ACAD to Watchlist
Sign Up

Overall POWR Rating

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 240 in Medical - Pharmaceuticals

See all "A" rated Strong Buy stocks

ACAD Stock Summary

  • For ACAD, its debt to operating expenses ratio is greater than that reported by only 4.71% of US equities we're observing.
  • With a price/sales ratio of 18.63, Acadia Pharmaceuticals Inc has a higher such ratio than 92.2% of stocks in our set.
  • ACAD's equity multiplier -- a measure of assets relative to shareholders'equity -- is greater than that of just 10.2% of US stocks.
  • If you're looking for stocks that are quantitatively similar to Acadia Pharmaceuticals Inc, a group of peers worth examining would be ESTC, GWPH, PACB, UTHR, and MRAM.
  • ACAD's SEC filings can be seen here. And to visit Acadia Pharmaceuticals Inc's official web site, go to

ACAD Stock Price Chart Interactive Chart >

Price chart for ACAD

ACAD Price/Volume Stats

Current price $46.45 52-week high $58.72
Prev. close $47.35 52-week low $30.02
Day low $45.35 Volume 1,325,700
Day high $47.67 Avg. volume 1,444,533
50-day MA $40.91 Dividend yield N/A
200-day MA $44.08 Market Cap 7.32B

ACADIA Pharmaceuticals Inc. (ACAD) Company Bio

Acadia Healthcare Company is a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in neurological and related central nervous system disorders. The company was founded in 1993 and is based in San Diego, California.

ACAD Latest News Stream

Event/Time News Detail
Loading, please wait...

ACAD Latest Social Stream

Loading social stream, please wait...

View Full ACAD Social Stream

Latest ACAD News From Around the Web

Below are the latest news stories about Acadia Pharmaceuticals Inc that investors may wish to consider to help them evaluate ACAD as an investment opportunity.

ACADIA Pharmaceuticals, Inc. (ACAD) CEO Steve Davis Presents at Cantor Virtual Global Healthcare Conference (Transcript)

ACADIA Pharmaceuticals, Inc. (ACAD) Cantor Virtual Global Healthcare Conference September 16, 2020 11:00 AM ET Company Participants Steve Davis - Chief Executive Officer Michael Yang - Chief Commercial Officer Conference Call Participants Charles Duncan - Cantor Fitzgerald Presentation Charles Duncan Good morning. So, welcome to day two of 2020 Cantor...

SA Transcripts on Seeking Alpha | September 16, 2020

ACADIA Pharmaceuticals Inc. (ACAD) CEO Steve Davis Presents at Morgan Stanley 18th Annual Global Healthcare Conference (Transcript)

ACADIA Pharmaceuticals Inc. (ACAD) Morgan Stanley 18th Annual Global Healthcare Conference September 14, 2020 03:45 PM ET Company Participants Steve Davis - CEO Serge Stankovic - President Elena Ridloff - CFO Conference Call Participants Jeff Hung - Morgan Stanley Presentation Jeff Hung Welcome to the Morgan Stanley Global Healthcare Conference....

SA Transcripts on Seeking Alpha | September 14, 2020

SHAREHOLDER ALERT: Stephens & Stephens LLP Investigating the Officers and Directors of ACADIA Pharmaceuticals Inc. (ACAD)

Stephens & Stephens LLP is investigating the officers and directors of ACADIA Pharmaceuticals Inc. (NasdaqGS: ACAD) for breach of fiduciary duties on the part of its directors and management.

Yahoo | July 30, 2020

Acadia Pharmaceuticals (ACAD) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Acadia (ACAD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Yahoo | July 29, 2020

People with Dementia and Caregivers Share the Significant Burden of Visual Hallucinations and Paranoid Delusions, New Survey Highlights

UsAgainstAlzheimer’s, the Lewy Body Dementia Association and ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD) today announced the results of a qualitative and quantitative survey that explored the impact of dementia-related psychosis on more than 200 patients to better understand the patient-centered experience of symptoms and unmet treatment needs. Both patients and caregivers responded to the survey. These data were presented today in two posters during the Alzheimer's Association International Conference® (AAIC) virtual event, convening July 27-31, 2020.

Yahoo | July 29, 2020

Read More 'ACAD' Stories Here

ACAD Price Returns

1-mo 10.23%
3-mo 11.74%
6-mo -0.30%
1-year 8.04%
3-year 35.19%
5-year 15.60%
YTD 8.58%
2019 164.56%
2018 -46.30%
2017 4.40%
2016 -19.10%
2015 12.28%

Continue Researching ACAD

Here are a few links from around the web to help you further your research on Acadia Pharmaceuticals Inc's stock as an investment opportunity:

Acadia Pharmaceuticals Inc (ACAD) Stock Price | Nasdaq
Acadia Pharmaceuticals Inc (ACAD) Stock Quote, History and News - Yahoo Finance
Acadia Pharmaceuticals Inc (ACAD) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.6795 seconds.